Results 31 to 40 of about 120 (83)

Cholesterol metabolites and tumor microenvironment: the road towards clinical translation. [PDF]

Cancer Immunol Immunother, 2016
Raccosta L, Fontana R, Corna G, Maggioni D, Moresco M, Russo V.   +5 more
europepmc   +1 more source

T cell responses to tumor: how dominant assumptions on immune activity led to a neglect of pathological functions, and how evolutionary considerations can help identify testable hypotheses for improving immunotherapy. [PDF]

Cancer Immunol Immunother, 2018
Kallikourdis M.
europepmc   +1 more source

Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies. [PDF]

Cancer Immunol Immunother, 2015
Castelli C, Rivoltini L, Rodolfo M, Tazzari M, Belgiovine C, Allavena P.   +5 more
europepmc   +1 more source

Overcoming the toxicity hurdles of genetically targeted T cells. [PDF]

Cancer Immunol Immunother, 2015
Casucci M, Hawkins RE, Dotti G, Bondanza A.   +3 more
europepmc   +1 more source

Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. [PDF]

Cancer Immunol Immunother, 2018
Petitprez F, Vano YA, Becht E, Giraldo NA, de Reyniès A, Sautès-Fridman C, Fridman WH.   +6 more
europepmc   +1 more source

[Acute fibrinous and organizing pneumonia]. [PDF]

Rev Port Pneumol (2006), 2010
Santos C, Fradinho F, Catarino A, Chaves Loureiro M.   +3 more
europepmc   +2 more sources

Armed antibodies for cancer treatment: a promising tool in a changing era. [PDF]

Cancer Immunol Immunother, 2015
Danielli R, Patuzzo R, Ruffini PA, Maurichi A, Giovannoni L, Elia G, Neri D, Santinami M.   +7 more
europepmc   +1 more source

Developments in cancer vaccines for hepatocellular carcinoma. [PDF]

Cancer Immunol Immunother, 2016
Buonaguro L, HEPAVAC Consortium.
europepmc   +1 more source

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy. [PDF]

Cancer Immunol Immunother, 2019
Maio M, Coukos G, Ferrone S, Fox BA, Fridman WH, Garcia PL, Lahn M, Provendier O, Russo V, Rüttinger D, Shalabi A, Trajanoski Z, Viallet J, Wolchok JD, Ibrahim R.   +14 more
europepmc   +1 more source

Human CD34/CD90 ASCs are capable of growing as sphere clusters, producing high levels of VEGF and forming capillaries. [PDF]

PLoS One, 2009
De Francesco F, Tirino V, Desiderio V, Ferraro G, D'Andrea F, Giuliano M, Libondi G, Pirozzi G, De Rosa A, Papaccio G.   +9 more
europepmc   +1 more source